The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A
2a
adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).
[EN] A2A ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RECEPTEUR D'ADENOSINE A2A
申请人:BIOGEN IDEC INC
公开号:WO2004092173A2
公开(公告)日:2004-10-28
The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).